A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer
his randomized phase II trial studies radiation therapy to see how well it works in treating patients with prostate cancer.
The purpose of this study is to demonstrate that 1-year health-related quality of life (HRQOL) for at least one hypofractionated arm is not significantly lower than baseline as measured by the Bowel and Urinary domains of the Expanded Prostate Cancer Index Composite (EPIC) instrument.
- IRB Number: 1204008432 (RTOG0938)
- Research Study Identifier: TX2472
- Principal Investigator: Peter Johnstone, MD
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required